1093.HK CSPC Pharma (HKSE) down 9.00% pre-market 31 Jan 2026: AstraZeneca impact
The most active Hong Kong stock this pre-market session is CSPC Pharmaceutical Group Limited (1093.HK stock), trading at HK$9.60, down 9.00% after heavy volume. Shares opened at HK$10.94 and are trading between HK$9.32 and HK$10.96 so far. Volume is already 570,493,236 shares, about 5.04 times the daily average. The move follows news of a licensing deal with AstraZeneca and triggered active intraday selling and position reshuffling on the HKSE in Hong Kong.
1093.HK stock market snapshot and activity
CSPC (1093.HK stock) is priced at HK$9.60 pre-market after a HK$0.95 fall from the previous close of HK$10.55.
Trading shows 570,493,236 shares exchanged versus an average volume of 113,253,339, roughly 5.04x normal, placing the name at the top of most-active lists on the HKSE.
Why the price moved: AstraZeneca deal and news flow
Investors reacted to reports that AstraZeneca will license CSPC’s weight-loss peptide programs and could pay up to US$18.5 billion in milestone and commercial payments according to Reuters and related outlets. Reuters and CNBC coverage amplified trading as funds re-priced upside and locked profits.
Financials and valuation for 1093.HK stock
CSPC reports EPS HK$0.38 and a trailing PE of 28.13, with PB around 3.27 and dividend yield near 2.25%.
Market cap stands at HKD 122106009015.00 and key ratios show a strong current ratio 2.24, low debt-to-equity 0.01, and a gross margin of 66.72%, suggesting operational strength despite a modest revenue decline year-over-year.
Technicals and trading signals for 1093.HK stock
Momentum indicators show near-overbought readings with RSI 69.45 and Stochastic %K 93.80, while ADX at 28.79 indicates a strong short-term trend.
Intraday volatility is elevated (ATR 0.34) and the stock sits around the upper Bollinger band (upper HK$9.49), warning that the immediate move may be profit-taking rather than a structural shift.
Meyka AI grade and model forecast for 1093.HK stock
Meyka AI rates 1093.HK with a score out of 100: 66.68 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects monthly HK$9.93 (+3.44% vs HK$9.60), quarterly HK$9.17 (-4.48%), and yearly HK$11.49 (+19.66%). Forecasts are model-based projections and not guarantees.
Risks, catalysts and sector context for 1093.HK stock
Key catalysts include formal deal terms, clinical readouts for the weight-loss peptides, and the March earnings announcement (earnings announcement date 2026-03-25).
Risks include longer receivables (days sales outstanding 126.56), slower revenue growth (-6.13% FY 2024), and valuation compression if market sentiment turns; Healthcare sector average PE is 29.06, close to CSPC’s level.
Final Thoughts
CSPC (1093.HK stock) leads pre-market activity in Hong Kong after a sharp 9.00% drop to HK$9.60 on record volume. The immediate driver is the AstraZeneca licensing reports that re-price global rights for CSPC’s peptide programs. Valuation metrics show a PE of 28.13, PB 3.27, and dividend yield 2.25%, which keeps the stock near sector norms. Meyka AI’s forecast model projects a one-year target of HK$11.49, implying +19.66% upside versus the current price. Given the high volume and mixed technicals, the model and our grade (Meyka AI rates 1093.HK with a score out of 100: 66.68, Grade B, HOLD) suggest monitoring near-term news flow and waiting for confirmation before adding new exposure. Forecasts are model-based projections and not guarantees; active traders should manage risk with clear stops and consider the March earnings date as a liquidity event
FAQs
What is driving the pre-market move in 1093.HK stock?
The pre-market drop reflects news of a licensing deal with AstraZeneca and heavy volume. Traders are re-pricing global rights for CSPC’s weight-loss peptides, causing short-term profit-taking and higher intraday volatility in 1093.HK stock.
What is Meyka AI’s outlook for 1093.HK stock?
Meyka AI’s forecast model projects a yearly level of HK$11.49, implying +19.66% versus the current HK$9.60. The model and grade (66.68, B, HOLD) flag upside but recommend monitoring regulatory and deal milestones for 1093.HK stock.
Are valuation metrics supportive for 1093.HK stock?
CSPC posts EPS HK$0.38, PE 28.13, PB 3.27, and dividend yield 2.25%. These place 1093.HK stock roughly in line with the Healthcare sector, but growth and receivables timing remain near-term risks.
What trading signals should investors watch for 1093.HK stock?
Watch intraday volume, RSI near 69.45, and price relative to the upper Bollinger band. A break below HK$9.32 or a sustained move above HK$10.96 will clarify direction for 1093.HK stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
